Immunotherapy of cancer: Key findings and commentary on the third tegernsee conference

Oncologist

Volumn 15, Issue 1, 2010, Pages 112-118

  Rüttinger, Dominik ^a,b   Winter, Hauke ^a   Van Den Engel, Natasja K ^a   Hatz, Rudolf ^a   Jauch, Karl Walter ^a   Fox, Bernard A ^c   Weber, Jeffrey S ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MICROMET AG   (Germany)

^c EARLE A CHILES RESEARCH INSTITUTE   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Conferences; Immunotherapy; Tegernsee

Indexed keywords

ANTINEOPLASTIC AGENT; BIOVAXID; BISPECIFIC T CELL ENGAGER; BLINATUMUMAB; CANCER VACCINE; CATUMAXUMAB; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; LUCANIX; MONTANIDE ISA 51; OX40 ANTIBODY; PLACEBO; PROVENGE; REMOVAB; STIMUVAX; TOSITUMOMAB; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; LOW DRUG DOSE; MELANOMA; METASTASIS; MICROENVIRONMENT; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; GERMANY; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 75649120787     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0213     Document Type: Conference Paper

References (15)

1. Peeters M, Price T, Van Laethem JL. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: Where are we today? The Oncologist 2009;14:29 -39.
2. Wheatly-Price P, Shepherd FA. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 2008;3:1173-1184.
3. Ross JS, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. The Oncologist 2009;14:320 -368.
4. Ruter J, Barnett BG, Kryczek I et al. Altering regulatory T cell function in cancer immunotherapy: A novel means to boost the efficacy of cancer vaccines. Front Biosci 2009;14:1761-1770.
5. Korman A, Yellin M, Keler T. Tumor immunotherapy: Preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 2005;6: 582-591.
6. O'Day S, Weber J, Lebbe C et al. Effect of ipilimumab treatment on 18-month survival: Update of patients with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials [abstract 9033]. J Clin Oncol 2009;27(15 suppl).
7. Smits EL, Ponsaerts P, Berneman ZN et al. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. The Oncologist 2008;13:859-875.
8. Schellhammer PF, Higano C, Berger ER et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC) [abstract LBA 9]. Proc Am Urol Assoc 2009;104.
9. Schuster SJ, Neelapu SS, Gause BL et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results [abstract 2]. J Clin Oncol 2009;27(18 suppl).
10. Schwartzentruber DJ, Lawson D, Richards J et al. A phase III multiinstitutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract CRA9011]. J Clin Oncol 2009;27(18 suppl).
11. Lu L, Schafer P, Bartlett JB. Inhibition by lenalidomide of growth factor and hypoxia-induced signaling in endothelial and epithelial tumor cells, and effects with the tumor cell microenvironment [abstract e14620]. J Clin Oncol 2009;27.
12. Emens LA, Asquith JM, Leatherman JM et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocytemacrophage colony-stimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009;27:5911-5918.
13. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346 -2357.
14. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-5239.
15. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321: 974-977.